| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1045785181 |
| P356 | DOI | 10.2165/11592850-000000000-00000 |
| P698 | PubMed publication ID | 21913740 |
| P2093 | author name string | Philippe Rousselot | |
| André Delannoy | |||
| P2860 | cites work | Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia | Q29547900 |
| Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia | Q29614324 | ||
| The role of endothelial PI3Kgamma activity in neutrophil trafficking | Q30444751 | ||
| Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial | Q31085634 | ||
| A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias | Q33343973 | ||
| Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. | Q33374461 | ||
| A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study | Q33392436 | ||
| Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International | Q33412662 | ||
| Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin-dexamethasone (VAD) regimen | Q33490030 | ||
| A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. | Q33503445 | ||
| Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia | Q33632278 | ||
| Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia | Q34131844 | ||
| Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia | Q34146996 | ||
| Age-adapted induction treatment of acute lymphoblastic leukemia in the elderly and assessment of maintenance with interferon combined with chemotherapy. A multicentric prospective study in forty patients. French Group for Treatment of Adult Acute Ly | Q73717203 | ||
| Acute lymphoblastic leukemia in the elderly: The Edouard Herriot Hospital experience | Q73851828 | ||
| [Analysis of elderly patients, aged 60 years old or over, with acute lymphoblastic leukemia] | Q77760684 | ||
| Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche de | Q79527735 | ||
| Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison | Q79802931 | ||
| Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation | Q84755188 | ||
| A population-based cytogenetic study of adults with acute lymphoblastic leukemia | Q84865592 | ||
| Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia | Q34350665 | ||
| Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors | Q34378360 | ||
| T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993) | Q34612782 | ||
| Acute lymphoblastic leukemia in the elderly | Q34976235 | ||
| Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993 | Q35848955 | ||
| Philadelphia chromosome-positive acute lymphoblastic leukemia secondary to chemoradiotherapy for Ewing sarcoma. Report of two cases and concise review of the literature | Q35988959 | ||
| Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges | Q37007473 | ||
| STAT6-mediated suppression of erythropoiesis in an experimental model of malarial anemia | Q37082704 | ||
| Translation of the Philadelphia chromosome into therapy for CML. | Q37344094 | ||
| Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study | Q43863915 | ||
| Treatment of acute lymphoblastic leukemia in the elderly: an evaluation of interferon alpha given as a single agent after complete remission | Q43927379 | ||
| Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report | Q44113297 | ||
| Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). | Q44258484 | ||
| Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia | Q44468873 | ||
| Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century | Q44586145 | ||
| Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). | Q44598654 | ||
| Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate | Q44612967 | ||
| Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy | Q44854228 | ||
| Comparison of two regimens for the treatment of elderly patients with acute lymphoblastic leukaemia (ALL). | Q44918816 | ||
| Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. | Q46174384 | ||
| Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia | Q46611126 | ||
| Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy | Q46788868 | ||
| High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group | Q46847866 | ||
| High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia | Q46911787 | ||
| In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolid | Q47596252 | ||
| Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. | Q53268906 | ||
| Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia. | Q53454654 | ||
| Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25-year period. | Q54161705 | ||
| Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. | Q54574746 | ||
| Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group | Q56965948 | ||
| Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study | Q56997440 | ||
| BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros | Q57734316 | ||
| Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) | Q58414406 | ||
| Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) | Q58414415 | ||
| Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia | Q62607772 | ||
| Acute lymphoblastic leukemia in elderly: the Polish Adult Leukemia Group (PALG) experience | Q64048474 | ||
| Acute lymphoblastic leukemia in patients aged 60 years and over: a population-based study of incidence and outcome | Q67899699 | ||
| Acute lymphoblastic leukemia in the elderly | Q68551522 | ||
| Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy | Q69481809 | ||
| Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A Collaborative Study of the Group Français de Cytogénétique Hématologique | Q71010507 | ||
| Age-adapted moderate-dose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia | Q71562712 | ||
| Acute lymphoblastic leukemia in patients over 59 years of age. Experience in a single center over a 10-year period | Q72891398 | ||
| Acute lymphoblastic leukemia in the elderly. A twelve-year retrospective, single center study | Q73291286 | ||
| Underrepresentation of patients 65 years of age or older in cancer-treatment trials | Q73311140 | ||
| Prognostic factors in elderly acute lymphoblastic leukaemia | Q73476169 | ||
| P433 | issue | 9 | |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 749-764 | |
| P577 | publication date | 2011-09-01 | |
| P1433 | published in | Drugs & Aging | Q5308946 |
| P1476 | title | Optimal pharmacotherapeutic management of acute lymphoblastic leukaemia in the elderly | |
| P478 | volume | 28 |
| Q92479171 | Approach to the Adult Acute Lymphoblastic Leukemia Patient | cites work | P2860 |
Search more.